Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Allergy and Immunology

The Biology of "Twitchy" Cells: Types of MCAS

At a Glance

Mast Cell Activation Syndrome (MCAS) happens when mast cells inappropriately release chemicals like histamine. It is divided into three types: Secondary (triggered by outside allergies), Idiopathic (unknown cause), and Primary/Monoclonal (caused by genetic mutations like KIT D816V).

To understand why your body is reacting this way, it helps to look at the biology of the mast cell itself. These cells are essentially tiny “chemical grenades” filled with over 200 different substances, including histamine (which causes itching and swelling) and tryptase (a protein used to measure mast cell activity) [1][2].

Normally, these cells only “fire” (a process called degranulation) when they detect a threat, like a virus or a specific allergen [2][3]. In MCAS, the safety catch on these grenades is broken, and they release their chemicals too easily or too often [4][5].

The Three Categories of MCAS

Doctors divide MCAS into three types based on why the mast cells are misbehaving. This distinction is vital because it determines your long-term outlook and treatment options [6][5].

1. Secondary MCAS (The “External” Trigger)

In this type, the mast cells themselves are normal, but they are being constantly provoked by something else [5]. This is most often an IgE-mediated allergy (like a severe peanut or bee sting allergy), but it can also be triggered by chronic inflammatory conditions or infections [5][7].

2. Idiopathic MCAS (The “Unknown” Cause)

“Idiopathic” is a medical term meaning the cause is unknown. You meet all the official criteria for MCAS—your symptoms involve multiple systems, your tryptase rises during flares, and you respond to treatment—but doctors cannot find a genetic mutation or an underlying allergy to explain it [5][8].

3. Primary / Monoclonal MCAS (The “Internal” Error)

In Monoclonal MCAS (MMCAS), the problem is inside the mast cells’ “blueprints.” These patients have a clonal population of mast cells, meaning a group of cells that are all identical copies of one “broken” original cell [9][10].

The most common error is the KIT D816V mutation [11][10]. This mutation acts like a “stuck switch” on the KIT receptor (the control tower of the mast cell), telling the cell to stay active, grow, and survive longer than it should [12][13].

MMCAS vs. Systemic Mastocytosis (SM)

If you have the KIT D816V mutation or other “clonal” markers (like abnormal proteins called CD25 on the cell surface), you fall into the category of Primary MCAS [14][9]. However, there is a very important distinction between MMCAS and Systemic Mastocytosis (SM):

  • Systemic Mastocytosis (SM): In SM, the mast cells usually form “dense aggregates” (large clumps) in the bone marrow or other organs [14][15]. This is the “Major Criterion” for SM. However, a diagnosis of SM can also be made if a patient meets 3 “Minor Criteria” (like the KIT mutation, CD25+ expression, and a high baseline tryptase >20 ng/mL) even in the absence of dense aggregates [14][15].
  • Monoclonal MCAS (MMCAS): In MMCAS, you have the mutation and the “twitchy” clonal cells, but you do not meet the criteria for an SM diagnosis [9][11].

Think of MMCAS as having a few “bad actors” in the immune system that cause a lot of trouble, whereas SM is a situation where those bad actors have also built a larger stronghold [9]. Knowing if your MCAS is monoclonal is important because it may mean you are at a higher risk for severe reactions (anaphylaxis) and require closer monitoring. While MMCAS is treated symptomatically, if the disease eventually progresses to Systemic Mastocytosis, specialized drugs called tyrosine kinase inhibitors (like avapritinib, which are FDA-approved for SM) might then be used to target the KIT mutation directly [16][17].

You can read more about how doctors look for these differences in Pathology and Lab Reports and how they are handled in The Stepwise Approach: Treatment and Management.

Common questions in this guide

What is the difference between Primary, Secondary, and Idiopathic MCAS?
Secondary MCAS is triggered by external factors like severe allergies or inflammation. Primary (Monoclonal) MCAS is caused by an internal genetic error in the mast cells. Idiopathic MCAS means you have all the symptoms and elevated markers, but doctors cannot pinpoint an underlying allergy or genetic cause.
What does a KIT D816V mutation mean for my MCAS diagnosis?
The KIT D816V mutation is a genetic error that acts like a stuck switch, causing mast cells to stay active and survive longer than they should. Testing positive for this mutation indicates you have Primary or Monoclonal MCAS rather than the secondary or idiopathic forms.
How is Monoclonal MCAS different from Systemic Mastocytosis?
Both conditions involve abnormal mast cells with genetic mutations. However, in Systemic Mastocytosis, the mast cells form dense clumps or aggregates in the bone marrow or other organs. Monoclonal MCAS involves abnormal cells but lacks these large clusters.
Why is my baseline tryptase level important?
Tryptase is a protein used to measure mast cell activity. Having a baseline tryptase level consistently above 20 ng/mL when you are feeling relatively well can point toward a clonal mast cell disorder, helping your doctor decide if further genetic testing is needed.
Why might I need a bone marrow biopsy for MCAS?
A bone marrow biopsy helps doctors look for dense clumps of mast cells, abnormal markers like CD25, and the KIT D816V mutation. This comprehensive testing is the best way to determine if you have Monoclonal MCAS or Systemic Mastocytosis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my blood or bone marrow been tested for the KIT D816V mutation?
  2. 2.If I have the KIT mutation but don't meet the full criteria for Systemic Mastocytosis, is my diagnosis considered Monoclonal MCAS (MMCAS)?
  3. 3.Do my mast cells show abnormal markers like CD25 or CD2 on flow cytometry?
  4. 4.How does knowing the 'type' of my MCAS (Primary, Secondary, or Idiopathic) change my long-term treatment plan?
  5. 5.If my MCAS is 'Primary' or 'Monoclonal,' are there specific medications like tyrosine kinase inhibitors that we should consider if the disease progresses?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview.

    Matito A, Escribese MM, Longo N, et al.

    Journal of investigational allergology & clinical immunology 2021; (31(6)):461-470 doi:10.18176/jiaci.0675.

    PMID: 33541851
  2. 2

    Unlocking the Non-IgE-Mediated Pseudo-Allergic Reaction Puzzle with Mas-Related G-Protein Coupled Receptor Member X2 (MRGPRX2).

    Kumar M, Duraisamy K, Chow BK

    Cells 2021; (10(5)) doi:10.3390/cells10051033.

    PMID: 33925682
  3. 3

    Reclassifying Anaphylaxis to Neuromuscular Blocking Agents Based on the Presumed Patho-Mechanism: IgE-Mediated, Pharmacological Adverse Reaction or "Innate Hypersensitivity"?

    Spoerl D, Nigolian H, Czarnetzki C, Harr T

    International journal of molecular sciences 2017; (18(6)) doi:10.3390/ijms18061223.

    PMID: 28590439
  4. 4

    Neuropsychiatric Manifestations of Mast Cell Activation Syndrome and Response to Mast-Cell-Directed Treatment: A Case Series.

    Weinstock LB, Nelson RM, Blitshteyn S

    Journal of personalized medicine 2023; (13(11)) doi:10.3390/jpm13111562.

    PMID: 38003876
  5. 5

    Diagnosis and Management of Patients With Mast Cell Activation Syndromes: Status 2026.

    Akin C, Gülen T, Castells MC, et al.

    The journal of allergy and clinical immunology. In practice 2026; (14(1)):19-28 doi:10.1016/j.jaip.2025.10.046.

    PMID: 41285202
  6. 6

    Idiopathic mast cell activation syndrome is more often suspected than diagnosed-A prospective real-life study.

    Buttgereit T, Gu S, Carneiro-Leão L, et al.

    Allergy 2022; (77(9)):2794-2802 doi:10.1111/all.15304.

    PMID: 35364617
  7. 7

    [Research progress of mast cell activation syndrome].

    Ren HL, Yang YS, Sun JL

    Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 2021; (55(12)):1513-1517 doi:10.3760/cma.j.cn112150-20210728-00722.

    PMID: 34963253
  8. 8

    A Puzzling Mast Cell Trilogy: Anaphylaxis, MCAS, and Mastocytosis.

    Gülen T

    Diagnostics (Basel, Switzerland) 2023; (13(21)) doi:10.3390/diagnostics13213307.

    PMID: 37958203
  9. 9

    [Mast cell activation syndrome. About a clinical case].

    Cardona R, Muñoz-Ávila MA, Gómez-Henao C, et al.

    Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 2019; (66(4)):504-509 doi:10.29262/ram.v66i4.587.

    PMID: 32105433
  10. 10

    A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis.

    Carter MC, Desai A, Komarow HD, et al.

    The Journal of allergy and clinical immunology 2018; (141(1)):180-188.e3 doi:10.1016/j.jaci.2017.05.036.

    PMID: 28629749
  11. 11

    Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.

    Muñoz-González JI, García-Montero AC, Orfao A, Álvarez-Twose I

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2021; (127(4)):427-434 doi:10.1016/j.anai.2021.07.014.

    PMID: 34298172
  12. 12

    Confirmed Systemic Mastocytosis in a Pediatric Patient With Widespread Cutaneous Symptoms.

    Cahill JA, Suresh S, Livingston JR

    Pediatrics 2025; doi:10.1542/peds.2024-067915.

    PMID: 39904361
  13. 13

    Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis.

    Grootens J, Ungerstedt JS, Ekoff M, et al.

    EBioMedicine 2019; (43()):150-158 doi:10.1016/j.ebiom.2019.03.089.

    PMID: 30975542
  14. 14

    [Tryptase: A practical guide for the physician].

    Lobbes H, Reynaud Q, Mainbourg S, et al.

    La Revue de medecine interne 2020; (41(11)):748-755 doi:10.1016/j.revmed.2020.06.006.

    PMID: 32712042
  15. 15

    Review and Updates on Systemic Mastocytosis and Related Entities.

    Li JY, Ryder CB, Zhang H, et al.

    Cancers 2023; (15(23)) doi:10.3390/cancers15235626.

    PMID: 38067330
  16. 16

    Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation.

    Hartmann K, Alvarez-Twose I, Bernstein JA, et al.

    The Journal of allergy and clinical immunology 2026; (157(2)):409-418 doi:10.1016/j.jaci.2025.10.010.

    PMID: 41399928
  17. 17

    Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.

    Siebenhaar F, Broesby-Olsen S, Castells M, et al.

    Journal of the American Academy of Dermatology 2026; doi:10.1016/j.jaad.2026.02.025.

    PMID: 41690487

This page explains the biological types of MCAS for educational purposes. Always consult your allergist, immunologist, or hematologist for an accurate diagnosis and personalized treatment plan.

Get notified when new evidence is published on Mast Cell Activation Syndrome (MCAS).

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.